Search Results 321-330 of 17373 for hba1c

1. Addressing Diabetes Together - Clinical Trials

   About this study. Integration of Diabetes Prevention Program (DPP) and Diabetes Self Management Program (DSMP) into WellConnect.

2. Fenofibrate for Prevention of DR Worsening - Mayo Clinic

   HbA1c > 11.0% based on central laboratory value or if lab sample cannot be analyzed, recent result within 3 months. Systemic anti-VEGF or pro-VEGF treatment ...

3. A Study to Evaluate Safety and Effectiveness of G-POEM for Gastroparesis - Mayo Clinic

   Poorly controlled diabetes with HbA1c of greater than 10% at time of screening. New medications for gastroparesis-related symptoms started within 1 month ...

4. Phase 1/2a Clinical Trial Of PR001 (LY3884961) In Patients With Parkinson's Disease With At Least One GBA1 Mutation (PROPEL)

   Poorly controlled/not adequately managed diabetes (Screening glycosylated hemoglobin [HbA1C] ≥ 7%);; History of unstable angina, myocardial infarction ...

5. Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor Positive (ER+) Breast Cancer - Mayo Clinic

   Uncontrolled diabetes mellitus (despite therapeutic; compliance to intervention) as defined by a haemoglobin A1c (HbA1c) level more than 8% and/or ...

6. A Study to Evaluate the Safety and Effectiveness of Bimagrumab on Improvement in Total Lean Body Mass and Physical Performance Following Surgical Treatment of Hip Fracture. - Mayo Clinic

   ... HbA1C ≥ 8% or average blood glucose ≥ 9.0 mmol/l); Significant coagulopathy, platelet count less than 75,000/mm3, or anemia (hemoglobin less than 8.0 g/dL) ...

7. https://www.mayoclinic.org/arabic_patient_consumer_faq.xml

8. A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer - Mayo Clinic

   Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

9. Healthy Patient Invasive Hemodynamic Control Cohort for MACHD Registry - Mayo Clinic

   These will serve as healthy controls and will be used for comparisons in the analysis of data from the Mayo Clinic Adult Congenital Heart Disease Registry ( ...

10. A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/​A011-16) - Mayo Clinic

    * Glycated hemoglobin (HbA1c) \>10% within 28 days of Visit 1 * Platelet count \< 75,000/mm3 within 28 days of Visit 1 13. History of severe allergic or ...